2017-11-14T15:30:21-07:00 2016-12-31 990 2016-01-01 264489946 SAGE BIONETWORKS SAGE 2066672102 1100 Fairview Ave N Seattle WA 98109 Lara Mangravite President 2066672102 2017-11-14 140.107.149.39 2016 2021-01-29 14:40:06Z Lara Mangravite 1100 Fairview Ave N M1-C108 Seattle WA 98109 7415116 0 X www.sagebase.org X 2009 WA Sage Bionetworks is a strategic research organization with a mission to coordinate and link academic and commercial biomedical researchers, patients and citizens through a Commons that represents a new paradigm for genomics intellectual property, researcher cooperation and contributor evolved resources. This mission has several interdependent themes, including: conducting research on network models of disease; building the computational platform for the Commons; and activating public engagement. 7 6 50 6 0 0 6230208 5184360 1464553 2230376 1056 380 0 0 7695817 7415116 411920 546676 0 0 5824396 5959014 0 0 74040 2142861 2612392 8379177 9118082 -683360 -1702966 4810343 2986406 1001568 880597 3808775 2105809 Sage Bionetworks is a strategic research organization with a mission to coordinate and link academic and commercial biomedical researchers, patients and citizens through a Commons that represents a new paradigm for genomics intellectual property, researcher cooperation and contributor evolved resources. This mission has several interdependent themes, including: conducting research on network models of disease; building the computational platform for the Commons; and activating public engagement. Sage Bionetworks is a non-profit research organization that seeks to develop predictors of disease and accelerate health research through the creation of open systems, incentives, and standards. We create strategies and platforms that empower researchers to share and interpret data on a colossal scale, crowdsource tests for new hypotheses, and contribute to knowledge through community challenges. 0 0 5579286 3801708 5499055 Research Communities and Challenges: Sage Bionetworks conducts research independently as well as with collaborators worldwide across a variety of disease areas. We work to redefine how complex biological data is gathered, shared and used through open systems, incentives, and norms. Our work includes the building of platforms and services and undertaking research developing predictors relating to health. Major research projects initiated in 2016 included: *Cancer Systems Biology Consortium (CSBC) - Sage was named as the Coordinating Center for the NCI funded CSBC and Physical Sciences in Oncology Network program. This five-year award builds on the work of the NCI funded Sage Bionetworks' Center for Cancer Systems Biology from 2010 through 2015. * Model Organism Development and Evaluation for Late-Onset AD (MODEL-AD) Consortium - MODEL-AD builds upon the open-science approach and the big-data infrastructure established by the ongoing AMP-AD and M2OVE-AD Consortia. MODEL-AD focuses on the development of a new generation of 40 rodent models representing late onset AD to support disease biology and preclinical drug development. Sage runs the Knowledge Portal, the distribution site for data, analysis results, analytical methodology and research tools generated by the consortium. * iAtlas - Sage, together with the Institute for Systems Biology, was funded by the Cancer Research Institute to build iAtlas, an online database and web resource designed to help basic and clinical researchers navigate immunological data across multiple tumor types. * Tumor neoantigEn SeLection Alliance (TESLA) - In 2016, the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute launched TESLA, a global research alliance with 30 public and private groups to advance the development of more effective personalized cancer treatments. Sage will play a key role managing the bioinformatics and data analysis. In 2016, Sage continued to support the following research communities using Synapse to organize and share data as well as insights derived from their collaborations: * AMP AD Knowledge Portal - a premier repository and workspace for multi-omic data generated through the AMP-AD, M2OVE-AD and MODEL-AD consortia, a public private partnership with the goal of accelerating the development of new drugs for the treatment and prevention of Alzheimer's disease. * Colorectal Cancer Consortium - a collection of colorectal cancer researchers and data scientists from 15 academic, pharmaceutical, and non-profit partners, which represents the first effort to generate consensus cancer subtypes, taking a major step toward precision medicine in CRC. * CommonMind Consortium - a public-private pre-competitive partnership with the goal to generate and analyze large-scale genomic data from human subjects with neuropsychiatric disease and to make this data and the analytical results broadly available. Initial findings were published in September 2016. * Infectious Disease Resilience project - a project designed to identify common characteristics of individuals that are resilient to infectious disease as a mechanism to understand the underlying biology. Initial analysis of nearly 600,000 genomes was completed in 2016. * mPower Public Researcher Portal - a data access point for the mobile app-based study piloting new approaches to monitoring key indicators of Parkinson Disease progression and diagnosis. An updated version of the mPower iPhone study was released in 2016, the first to use Apple's new CareKit platform. * Progenitor Cell Biology Consortium (PCBC) - an NIH sponsored effort to identify and characterize progenitor cell lineages and to develop new strategies related to the transplantation of these cells. * PsychENCODE Consortium - a public integrated resource for human brain data with a focus on autism, mood disorders and psychoses. 2016 marked the first public release of data generated by the Consortium. * Synodos Consortium - a first-of-its-kind Neurofibromatosis research collaboration dedicated to defeating the rare genetic disorder neurofibromatosis type 2. * The Cancer Genome Atlas (TCGA) - with data from 12 cancers, TCGA is an ongoing effort to simultaneously analyze molecular platforms for patterns across cancer types. 2811656 618976 1781703 Mobile Health Sage's Mobile Health program is built around Bridge, a cloud-based collaborative science platform designed to incorporate open data, patient wisdom and public involvement into biomedical research. Bridge was first used to support the initial set of mobile app-based research studies launched on Apple's ResearchKit in 2015. Sage's work in mobile health continued to expand in 2016 and included the following projects: * PMI All of Us - Sage was named as a collaborator with The Scripps Research Institute (TSRI) in the Precision Medicine Initiative All of Us program to engage over one million participants in a study to improve the ability to prevent and treat disease based on individual differences in lifestyle, environment and genetics. Sage is responsible for the patient consent and data governance, community outreach and participant engagement aims of this five-year NIH funded program. Sage is also engaged in the scientific and software engineering work to develop new methodologies for measuring symptoms of health and disease. * Chronic Anemia - Development began in 2016 for this quality of life observational study conducted in partnership with Celgene. The study incorporates wearable and mobile technologies to assess mobility, cardiovascular health, cognitive performance, and quality of life assessments. * Football Players Health Study - Sage managed the design, development, and data hosting services for the Harvard TeamStudy Research Kit app, launched in March 2016. This study recruits both ex-NFL players and the general public to better understand the long-term effects of professional football on players' health. * Melanoma Mole Mapper - Mole Mapper, an app-based research study conducted by OHSU, is an effort to better understand melanoma by helping people track their own skin lesions with photographs. Sage supported the launch of the iPhone version of Mole Mapper in 2015 and released Mole Mapper Android in 2016. * Multiple Sclerosis - With an industry partner, Sage customized the mPower mobile app to assess the ability of mobile technology to monitor the severity of MS symptoms and to track relapse. * Parkinson Disease - In 2016, Sage released several new versions of mPower, the mobile health Parkinson's disease study launched with the introduction of Apple's ResearchKit in 2015. In March 2016, Sage released the first mPower dataset, representing millions of data points from over 9,500 participants participating in this first-of-its-kind mobile health study. * Sarcoidosis - Sage supported the development of a mobile app to support this University of Pennsylvania study focused on patient quality of life in 2016. The study launched in early 2017. * Resilience Project - Sage developed an iPhone app to support the Mount Sinai School of Medicine study on how genetic variation leads to resistance to a spectrum of common childhood genetic disorders. 0 0 0 8390942 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 1 0 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 19 0 50 1 0 0 0 0 0 0 0 0 0 0 X 7 6 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 0 1 0 0 X Diane Gary 2066673038 1100 Fairview Ave N Seattle WA 98109 Stephen Friend Chairman of the Board 1 0 X 65495 0 9127 Eric Schadt Director/Chair of Scientific Advisory Board 1 0 X 0 0 0 Jeff Hammerbacher Director 1 0 X 0 0 0 Tony Ford-Hutchinson Director 1 0 X 0 0 0 Gustavo Stolovitsky Director 1 0 X 0 0 0 Eric Topol Director 1 0 X 0 0 0 Lara Mangravite President 50 0 X 201053 0 30989 Diane Gary Secretary 50 0 X 154458 0 24806 John Wilbanks Chief Commons Officer 50 0 X 225815 0 32089 Mike Kellen Chief Technology Officer 50 0 X 198629 0 22302 Justin Guinney Vice President, Computational Oncology 50 0 X 166019 0 30300 Larsson Omberg Vice President, Systems Biology 50 0 X 142557 0 23480 Thea Norman Director, Strategic Development 50 0 X 159409 0 27095 Bruce Hoff Director, Synapse Team 50 0 X 149919 0 32833 Dwayne Jeng Principal SW Engineer 50 0 X 149691 0 7683 Erin Mounts Principle SW Engineer 50 0 X 148347 0 20739 Solly Sieberts Principal Scientist 50 0 X 146473 0 16022 1907865 0 277465 27 0 1 0 0 0 0 0 0 4212332 972028 197767 5184360 Scientific Collaborations 541711 2230376 2230376 0 0 0 0 0 0 2230376 380 0 0 380 0 0 0 0 0 0 0 0 0 0 0 0 0 0 7415116 2230376 0 380 X 443118 443118 0 0 103558 103558 0 0 1394762 1092251 284596 17915 0 0 0 0 3706907 3475054 202126 29727 238095 224026 13487 582 367390 332615 29795 4980 251860 235169 16020 671 74767 67385 6719 663 238858 216038 20772 2048 34367 30974 3088 305 0 0 0 0 0 0 0 0 0 0 1365160 1352546 2743 9871 5045 5045 0 0 27009 24342 2427 240 53817 48504 4836 477 0 0 0 0 388292 349956 34893 3443 271714 245339 24006 2369 0 0 0 0 36622 33006 3291 325 0 0 0 0 0 0 0 0 4687 4224 421 42 31450 28345 2826 279 80604 79447 1054 103 9118082 8390942 653100 74040 0 0 866729 699748 3509569 1687809 367983 545659 0 0 0 0 0 0 0 0 54082 45897 62146 54853 11980 7293 0 0 0 0 0 0 0 0 0 0 4810343 2986406 490503 546095 0 0 511065 334502 0 0 0 0 0 0 0 0 0 0 1001568 880597 X 361382 717273 3447393 1388536 0 0 3808775 2105809 4810343 2986406 -1702966 0 0 0 0 0 X 1 X 1 X 1 1 1 X 5014681 5154616 7808314 6230203 5050380 29258194 0 0 0 0 0 0 0 0 0 0 5014681 5154616 7808314 6230203 5050380 29258194 0 29258194 3146 1640 1802 1056 380 8024 0 0 0 0 0 0 1766523 1531308 1552869 1464542 2230377 8545619 37811837 0 0.77378 0.76847 X Schedule A, Part II, Line 10 Fee for service revenue from research collaborations RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 0 0 0 0 0 0 0 0 62146 0 54853 7293 0 0 0 0 7293 7415116 0 0 0 0 0 7415116 0 0 0 7415116 9118082 0 0 0 0 0 9118082 0 0 0 9118082 1 Europe (including Iceland and Greenland) 0 0 Grantmaking Data generation for our Coordinated Pediatric AML Treatment Options study 103558 0 0 103558 Europe (including Iceland and Greenland) Data generation for our Coordinated Pediatric AML Treatment Options study 103558 Electronic Funds Transfer 0 0 1 0 0 0 0 0 0 Schedule F, Part I, Line 2 Monitoring the use of grant funds: In some cases, grants received by Sage Bionetworks are passed on to sub-recipients through a sub-award agreement. The Grant Manager is responsible for initiating the sub-award agreement after obtaining budget approval from the PI and Operations Director. In issuing a sub-award, the Grant Manager is responsible for: obtaining verification of the sub-awardee's facilities and administrative rates and Single Audit Reports; reviewing the prime award special terms and conditions to determine whether they are applicable to the sub-award; and determining whether the sub-awardee meets all of the other administrative and regulatory requirements of the prime award. Once the sub-award has been issued, the Grant Manager is responsible for monitoring sub-award activity, including compliance with all reporting requirements. The Grant Manager is also responsible for forwarding the fully executed sub-award documents to the Accounting Manager to ensure proper billing. Payments are made only after the sub-award agreement has been fully executed by both parties. 1 Fred Hutchinson Cancer Research Center 1100 Fairview Ave N Seattle WA 98109 237156071 44325 0 Assist in high throughput drug screening and genomic profiling of patients at relapse to define patient specific drug sensitivity profile and their genomic/transcript composition for our Coordinated Pediatric AML Treatment Options project. Phoenix Children's Hospital 1919 E Thomas Road Phoenix AZ 85016 742421549 62721 0 Perform drug screening, molecular integration of data and clinical trial development as well as analysis and transfer of the large genomic data sets that will be integrated by the bioinformatical teams at each participating institution for our Coordinated Pediatric AML Treatment Options project. Oregon Health Sciences University 3181 SW Sam Jackson Park Rd Portland OR 97239 931176109 67303 0 Validate and assimilate data from functional and genomic data to facilitate their use in the cancer cloud hub, provide bioinformatics analyses and algorithm design to aid in the development of real-time models to predict treatment outcomes based on integrated data for each patient for our Coordinated Pediatric AML Treatment Options project. Institute for Medical Research Inc 508 Fulton St Durham NC 27705 561655431 125662 0 Project development, data curation, pilot analyses, develop open innovation challenge to crowd source study design, an build a colllaborative working group from participants and organizations for our "Resilience to Infection: an open innovation challenge to the community" project. University of South Alabama 307 N University Blvd No 130 Mobile AL 36608 630477348 6652 0 Provide data analyses for our "Resilience to Infection: an open innovation challenge to the community" project. Kasier Permanente 1730 Minor Ave Suite 1600 Seattle WA 98101 910511770 43526 0 Data/image generation for our Digital Mammography Challenge project. Icahn School of Medicine at Mount Sinai 1 Gustave L Levy Place New York NY 11029 136171197 64781 0 Data analyses for our Digital Mammography Challenge project Stanford University 450 Serra Mall Stanford CA 94305 941156365 22000 0 Create a baseline model for future comparison using existing framework for Digital Mammography Challenge. University of Washington University of Washington Seattle WA 98195 916001537 6148 0 Assist with our Digital Mammography Challenge 8 9 Schedule I, Part I, Line 2 In 2016, Sage Bionetworks issued grants, contributions, and prizes. Contributions were given in support of an awarded institution's project and prizes were awarded to research challenge winners. Monitoring the use of grant funds: In some cases, grants received by Sage Bionetworks are passed on to sub-recipients through a sub-award agreement. The Grant Manager is responsible for initiating the sub-award after obtaining budget approval from the PI and Operations Director. In issuing a sub-award, the Grant Manager is responsible for: obtaining verification of the sub-awardee's facilities and administrative rates and Single Audit Reports; reviewing the prime award special terms and conditions to determine whether they are applicable to the sub-award; and determining whether the sub-awardee meets all of the other administrative and regulatory requirements of the prime award. Once the sub-award has been issued, the Grant Manager is responsible for monitoring sub-award activity, including compliance with all reporting requirements. The Grant Manager is also responsible for forwarding the fully executed sub-award documents to the Accounting Manager to ensure proper billing. Payments are made only after the sub-award agreement has been fully executed by both parties X 1 1 X 0 0 0 0 0 0 0 0 0 Lara Mangravite President 201053 0 0 0 0 0 0 0 30989 0 232042 0 0 0 Stephen Friend Chairman of the Board 65495 0 0 0 0 0 0 0 9127 0 74622 0 0 0 Diane Gary Secretary 154458 0 0 0 0 0 0 0 24806 0 179264 0 0 0 John Wilbanks Chief Commons Officer 225815 0 0 0 0 0 0 0 32089 0 257904 0 0 0 Mike Kellen Director, Technology & Software Development 198629 0 0 0 0 0 0 0 22302 0 220931 0 0 0 Justin Guinney Director, Oncology 166019 0 0 0 0 0 0 0 30300 0 196319 0 0 0 Larsson Omberg Vice President, Systems Biology 142557 0 0 0 23480 0 0 0 0 0 166037 0 0 0 Thea Norman Director, Strategic Development 157409 0 0 0 0 0 0 0 27095 0 184504 0 0 0 Bruce Hoff Director, 149919 0 0 0 0 0 0 0 32833 0 182752 0 0 0 Dwayne Jeng Principal SW Engineer 149691 0 0 0 0 0 0 0 7683 0 157374 0 0 0 Erin Mounts Principle SW Engineer 148347 0 0 0 20739 0 0 0 0 0 169086 0 0 0 Solly Sieberts Principal Scientist 146473 0 0 0 16022 0 0 0 0 0 162495 0 0 0 Schedule J, Part I, Line 1a All travel is conducted per the company travel policy. Schedule J, Part I, Line 3 Setting executive compensation is the responsibility of the Board of Directors Compensation Committee. 0 0 0 0 Schedule M, Part I, Line 33 Received In-Kind legal services Form 990, Part VI, Section B, Line 11b The 990 is reviewed by the company's Vice President of Operations and President prior to filing. Form 990, Part VI, Section B, Line 12c Sage Bionetworks has a Financial Conflict of Interest Policy (FCOI) that complies with the National Institutes of Health-specific requirements promoting objectivity in research, 42 CFR Part 50 subpart F. On an annual basis, Sage Bionetworks Officers, Directors, and members of committees of the Board of Directors authorized to act on behalf of the board, and employees designated by the President of Sage Bionetworks, including any employees serving as an investigator on a federal/Public Health Services award, must review and update the Sage Bionetworks Annual Conflict of Interest Questionnaire. New employees serving as investigators are required to complete a FCOI form within 30 days of their start date. In addition, all investigators must submit an ad hoc disclosure of an Significant Financial Interest they acquire or discover during the course of the year within 30 days of discovering or acquiring the Significant Financial Interest. Forms are reviewed and any potential conflicts are referred to the President and outside counsel. Form 990, Part VI, Section B, Line 15 Executive compensation was set by the Board of Directors Compensation Committee. Form 990, Part VI, Section C, Line 19 The organization's financials are contained within its 990 returns. These returns are available to the public through organizations such as Guidestar, dedicated to publicizing information about nonprofit organizations. The organization's governing documents and conflict of interest policies are available upon request. Form 990, Part IX, Line 11g Scientific Research Expenses $445,756; Commons/Assembly Expenses $466,865; Platform/Scientific Computing Expenses $416,159; Fund Development Expenses $9,600; Professional Services Expenses $26,780 CPA Single Audit was not completed until the end of September.